Viscosupplementation Market Size & Share 2026-2035

Viscosupplementation Market Size

The viscosupplementation market was valued at USD 4.9 billion in 2025. The market is expected to grow from USD 5.3 billion in 2026 to USD 11 billion in 2035, growing at a CAGR of 8.5%, according to the latest report published by Global Market Insights, Inc.


The growth of the market is attributed to the rising cases of osteoarthritis (OA), particularly knee OA. Due to increasing age, the geriatric population is more susceptible to arthritis, which demands effective treatments. According to the World Health Organization (WHO), around 528 million people worldwide were living with osteoarthritis in 2019, with the knee being the most commonly affected joint, accounting for about 365 million cases globally. The growing prevalence of OA significantly increases the demand for non-surgical treatment options such as hyaluronic acid injections, which help improve joint lubrication and reduce pain in affected patients.

Further, a study published in The Lancet Rheumatology by the Institute for Health Metrics and Evaluation (IHME) confirms a significant increase in the global burden of osteoarthritis, estimating a 132.2% rise in total cases from 1990 to 2020. The forecast suggests that by 2050, there will be an estimated 1 billion cases of osteoarthritis. These growing cases are expected to drive the demand for effective osteoarthritis drugs such as viscosupplement agents.
 

The market witnessed considerable growth between 2022 and 2024, growing from USD 3.9 billion in 2022 to USD 4.5 billion in 2024. Rising clinical use of intra-articular hyaluronic acid injections and the growing trend of minimally invasive treatments are some of the factors driving this growth. Research has proven that hyaluronic acid injections are effective in improving pain, stiffness, and joint function in patients suffering from osteoarthritis of the knee for some months after treatment. Healthcare practitioners highly recommend minimally invasive procedures for the management of OA, thus increasing the adoption of viscosupplementation procedures worldwide.
 

Viscosupplementation is a medical procedure used for OA treatment by injecting HA into the affected joints, particularly knee OA. These therapies restore joint lubrication, reduce friction, alleviate pain, and enhance mobility, thereby delaying the need for surgical interventions. It is a minimally invasive alternative to surgery and is used widely in orthopedic and sports medicine. The top players in the global viscosupplementation market include Zimmer Biomet, Anika Therapeutics, Seikagaku Corporation, Sanofi, and Bioventus. These players contribute to the market through the development and commercialization of hyaluronic acid–based injectable therapies, continuous product innovation, and strong global distribution networks for osteoarthritis treatment.
 

Viscosupplementation Market Trends

• The use of hyaluronic acid injections into the knee joint is becoming popular as a non-surgical intervention for the treatment of knee OA to reduce pain and enhance the functioning of the knee. Scientific studies suggest that the injection of hyaluronic acid into the knee joints can give symptomatic relief to patients for a period of 4 to 6 months. Thus, it is an effective treatment for patients looking for options other than surgery.
   
• In addition, growing preference to minimally invasive procedures for managing joint pain is gaining traction in recent years. Viscosupplementation injections facilitate joint lubrication and mobility. At the same time, they avoid the potential harm that comes with surgery. Scientific studies have revealed that viscosupplementation can delay knee replacement surgery in patients by 2-3 years. Thus, a high volume of patients is shifting towards viscosupplementation, thereby driving the market growth.
   
• Further, advancements in the technology of hyaluronic acids, especially cross-linked hyaluronic acids, are improving the durability of treatment. The formulations are improving the viscosity of the injected product within the joint, thereby providing pain-relieving benefits for up to six months or longer after a single injection.
   

• Also, ongoing emphasis on improving HA properties through cross-linking technology reinforces its therapeutic potential, encouraging higher investments in R&D, leading to intense competition with innovative formulations.
   
• For instance, in November 2022, Anika Therapeutics announced study results demonstrating the superiority of Cingal, a combination of cross-linked HA-based single-injection viscosupplement over the triamcinolone hexacetonide steroid. The study showed that Cignal demonstrated 71% pain improvement at baseline, signifying strong clinical benefits. These findings are expected to prompt certainty in combination therapies for OA pain, thereby driving the market demand.
   
• Lastly, the rising number of sports-related joint injuries and an increasing number of physically active individuals are contributing to the growing demand for viscosupplementation therapies. According to the U.S. Centers for Disease Control and Prevention (CDC), over 8.6 million sports and recreation-related injuries occur annually in the U.S., many involving joints such as the knee, which can require treatments like viscosupplementation to manage pain and restore joint function.
   
• Additionally, several advantages such as extended efficacy, minimized healthcare costs, and long-term outcomes have made viscosupplementation a preferred choice for OA treatment. As a result, the healthcare providers are increasingly shifting towards advanced HA formulations.
   

Viscosupplementation Market Analysis

Based on the product, the market is segmented into single injection, 3 injections, and 5 injections. The 3 injections segment generated the largest market revenue of USD 2.3 billion in 2025 and is projected to reach USD 5.3 billion by 2035, growing at a CAGR of 8.7%.
 

• The effectiveness of the three-injection regimen in alleviating OA symptoms and enhancing joint function is well-documented clinically. Therefore, it is the standard treatment protocol in viscosupplementation.
   
• Also, the increasing adoption of three injections can be attributed to its optimal treatment duration, flexibility in dosage and administration, convenient treatment schedule, and widespread clinical acceptance. Owing to these factors, this segment is expected to significantly grow over the forthcoming years.
   
• The single injection segment, on the other hand, is expected to grow at a CAGR of 8.9% over the forecast period, owing to its convenience, reduced number of clinical visits, improved patient compliance, and advancements in cross-linked hyaluronic acid formulations that provide longer-lasting pain relief with a single dose.

Based on the source of origin, the viscosupplementation market is categorized into avian origin and non-avian origin. The non-avian origin segment accounted for the highest market share of 71.5% in 2025 and is anticipated to reach USD 7.8 billion in revenue by the end of 2035.
 

• High growth can be attributed to factors such as reduced risk of allergic reactions, ethical and environmental considerations, as well as the assurance of consistency and purity. Its wider acceptance in the market contributes to its increasing popularity and adoption in viscosupplementation. 
   
• Moreover, as demand for non-animal-derived products continues to rise, non-avian viscosupplements are poised to play an increasingly significant role in meeting patient needs and preferences. For instance, products such as Monovisc, Durolane, and Neovisc are all non-avian based. Each of these belongs to the latest generation of HA injection products and has a high molecular weight relative to initial HA formulations.
   
• Therefore, advances in biotechnology and fermentation processes for the production of non-avian products are anticipated to bolster market growth.
   

Based on the end use, the market is categorized into hospitals, orthopedic clinics, ambulatory surgical centers (ASCs), and other end users. The hospitals segment is expected to witness high growth of 8.7% and is poised to reach USD 5.4 billion by 2035.
 

• The hospitals segment accounts for a significant share of the viscosupplementation market due to the high volume of osteoarthritis patients seeking diagnosis and treatment in hospital settings.
   
• Hospitals are often equipped with advanced orthopedic care facilities, imaging technologies, and skilled healthcare professionals, enabling accurate diagnosis and administration of intra-articular injections such as viscosupplementation.
   
• Additionally, the availability of specialized orthopedic departments and greater patient trust in hospital-based treatments contribute to the higher adoption of viscosupplementation procedures in these settings, thereby supporting the segment’s dominant market share.

North America Viscosupplementation Market

North America dominated 42.1% share of the viscosupplementation industry in 2025.
 

• North America holds a significant share of the global viscosupplementation industry, primarily driven by the high prevalence of osteoarthritis and strong healthcare infrastructure in the region.
   
• According to the U.S. Centers for Disease Control and Prevention (CDC), about 1 in 4 adults in the U.S. (around 58.5 million people) are projected to have doctor-diagnosed arthritis by 2040, indicating a growing burden of joint-related conditions.
   
• The region also benefits from high healthcare expenditure, widespread availability of advanced orthopedic treatments, and strong presence of key market players offering hyaluronic acid-based viscosupplementation therapies.
   
• Additionally, increasing awareness regarding non-surgical treatment options and rising adoption of minimally invasive procedures further support North America’s dominant position in the global market.
   

The U.S. held a significant position in the North America viscosupplementation market and was valued at USD 1.6 billion and 1.7 billion in 2022 and 2023, respectively. The market size reached USD 1.9 billion in 2025, growing from USD 1.8 billion in 2024.
 

• Osteoarthritis is increasingly prevalent in the U.S. population, with clinical studies stating there are over 100 types of arthritis, and osteoarthritis is the most prevalent form of arthritis.
   
• The estimates suggest that the disease affects the ageing population, with 43% of people suffering from osteoarthritis aged 65 & above. These elderly individuals are more susceptible to developing osteoarthritis due to factors such as cumulative joint wear and tear, age-related changes in cartilage structure, and reduced joint resilience.
   
• Thus, as the geriatric population grows, the prevalence of osteoarthritis is expected to rise, driving demand for effective management strategies, including viscosupplementation.
   
• Furthermore, expanding FDA approvals for single and multi-injection formulations, along with the continuous R&D investment, foster market growth in the country.
   
• Moreover, patients receiving multiple treatment cycles of Gel-One showed no increased risk of side effects. Gel-One is a viscosupplement designed specifically for the treatment of osteoarthritis of the knee.
   
• It contains cross-linked hyaluronate, a form of hyaluronic acid that is modified to enhance its durability and longevity within the joint. Thus, the availability of such advanced formulations is anticipated to drive the market growth
   

Europe Viscosupplementation Market

Europe accounts for a notable share of the global viscosupplementation industry, supported by the rising prevalence of osteoarthritis, a rapidly ageing population, and well-established healthcare systems across the region.
 

• According to the European Commission, nearly 20% of the population in the European Union is aged 65 years and above, increasing the risk of degenerative joint diseases such as osteoarthritis.
   
• The growing elderly population, combined with strong access to orthopedic care and increasing adoption of minimally invasive pain management therapies, is driving the demand for viscosupplementation treatments in the region.
   
• Additionally, the presence of leading pharmaceutical and medical device companies, along with ongoing clinical research in hyaluronic acid-based therapies, further supports the regional revenue share.
   

Germany is poised to achieve significant growth in the Europe viscosupplementation market.
 

• Germany’s leadership is driven by its growing ageing population, rising incidence of OA cases, and healthcare infrastructure.
   
• According to a study published by the National Institutes of Health (NIH), approximately 17.9% of adults aged 18 years and above are affected by osteoarthritis (OA). The study also reported that the prevalence is higher among women (21.8%) compared to men (13.9%), highlighting the significant burden of OA and the growing need for effective treatment options such as viscosupplementation.
   
• Further, the country’s favorable reimbursement policies, regulatory support and high patient awareness regarding early OA treatment strengthen its position in the market.
   

Asia Pacific Viscosupplementation Market

The Asia Pacific region is expected to witness significant growth, driven by the rising prevalence of osteoarthritis, rapidly ageing populations, and improving healthcare infrastructure across countries such as China, Japan, and India.
 

• According to the United Nations, the population aged 65 years and above in Asia is projected to reach nearly 922 million by 2050, increasing the risk of age-related joint disorders such as osteoarthritis.
   
• Additionally, increasing healthcare expenditure, growing awareness of minimally invasive orthopedic treatments, and expanding access to advanced medical therapies are contributing to the rising adoption of viscosupplementation procedures in the region.
   
• The presence of a large patient pool and increasing investments in healthcare are further expected to support strong market growth in the Asia Pacific.
   

The China viscosupplementation market is anticipated to witness rapid growth in the Asia Pacific market in the coming years.
 

• The large ageing population, with rising OA prevalence and expanding healthcare infrastructure, drives China’s leadership in the Asian market. As per the World Health Organization (WHO), with over 300 million people aged above 50 and projected to reach 402 million by 2040, this population is prone to several conditions including joint pain.
   
• Also, leading domestic manufacturers and accessibility to a range of HA-based injection and viscosupplementation treatments boost its adoption.
   
• Similarly, growing healthcare expenditure in the country, along with surging investment in R&D activities to introduce advanced joint pain injections favors business growth.
   

Latin America Viscosupplementation Market

Brazil held a prominent position in the Latin America viscosupplementation industry.
 

• The expanding healthcare infrastructure, growing ageing population with OA and high burden of musculoskeletal disorders in the country fuel the demand for minimally invasive treatment, thereby driving the demand for viscosupplementation products.
   
• Minimally invasive treatments, including viscosupplementation, can result in lower overall healthcare costs compared to traditional surgical procedures. These treatments often require fewer resources, shorter hospital stays, and decreased postoperative care, leading to cost savings for both patients and healthcare systems.
   
• Additionally, the presence of leading pharmaceutical companies and government initiatives supporting orthopedic care further contributes to the country’s growth in the Latin America market.
   

Middle East & Africa Viscosupplementation Market

• South Africa represents an emerging market for viscosupplementation, supported by the rising burden of osteoarthritis, increasing awareness of joint health, and gradual improvements in orthopedic care services.
   
• According to the World Health Organization (WHO), musculoskeletal conditions such as osteoarthritis are among the leading causes of disability worldwide, and their impact is increasingly observed in middle-income countries including South Africa.
   
• The country’s ageing population and growing prevalence of obesity, identified as a major risk factor for osteoarthritis, are contributing to higher demand for joint pain management treatments.
   
• In addition, expanding private healthcare services and the increasing availability of advanced orthopedic therapies are expected to support the adoption of viscosupplementation procedures in South Africa.
   

Viscosupplementation Market Share

The viscosupplementation industry is characterized by the presence of several global pharmaceutical and medical device companies focusing on the development of advanced hyaluronic acid (HA)-based formulations for osteoarthritis management. Key players such as Zimmer Biomet, Anika Therapeutics, Seikagaku Corporation, Sanofi, and Bioventus hold a combined market share of ~65% in the global market. These companies compete through product innovation, strategic collaborations, and expansion of their product portfolios. Companies are increasingly investing in research and development to introduce single-injection and cross-linked HA formulations that provide longer-lasting pain relief and improved patient outcomes. Additionally, partnerships with healthcare providers and expansion of distribution networks are helping these companies strengthen their market presence and address the growing demand for minimally invasive treatments for osteoarthritis.
 

Viscosupplementation Market Companies

Few of the prominent players operating in the viscosupplementation industry include:

• Anika Therapeutics
• APTISSEN
• Avanos Medical
• Biotech Healthcare
• Bioventus
• Ferring Pharmaceuticals
• Fidia Pharma
• IBSA Pharma
• Premier Surgical
• Sanofi
• Seikagaku Corporation
• Stellar Pharmaceuticals
• TRB Pharma
• Zimmer Biomet
   
• Sanofi

Sanofi has established a strong presence in the viscosupplementation market through its hyaluronic acid injection portfolio, particularly Synvisc-One. The product is widely used for the treatment of Osteoarthritis, especially knee osteoarthritis, where it helps restore the viscoelastic properties of synovial fluid, thereby reducing pain and improving joint mobility in patients who have not responded adequately to conservative therapies such as analgesics or physical therapy.
 

• Anika Therapeutics

Anika Therapeutics possesses a strong focus on the development of innovative HA products particularly in orthopedics. The company strives to develop innovative cross-linked HA-based combination therapies addressing the need for long-term treatment outcomes and joint lubrication.
 

Viscosupplementation Industry News

• In February 2024, IBSA UK, a subsidiary of the Swiss-based IBSA Group, launched its advanced SINOVIAL range in the UK for osteoarthritis treatment. The product features a proprietary formulation using NAHYCO technology, combining high and low molecular weight hyaluronic acid for optimal joint lubrication.
   
• In January 2024, Zimmer Biomet launched VISCO‑3, a three-injection high molecular weight hyaluronate treatment for moderate-stage knee osteoarthritis in select global markets. Clinical trial data showed a 52% reduction in pain in 12 weeks, extended relief up to six months, and a favorable safety profile.
   
• In December 2021, Avanos Medical acquired OrthogenRx, an emerging leader in viscosupplementation therapies for knee OA pain. This acquisition aimed to enhance the Avanos chronic pain portfolio providing solutions for OA treatment.
   
• In August 2021, Seikagaku introduced Hylink, an intra-articular single injection viscosupplements for the treatment of knee OA in Taiwan. Hylink is an advanced cross-linked hyaluronate hydrogel formulated for the long-lasting improvement of viscoelasticity in knee joint cavities.
   

The viscosupplementation market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Market, By Product

• Single injection
• 3 injections
• 5 injections

Market, By Source of Origin

• Avian origin
• Non-avian origin

Market, By End Use

• Hospitals
• Orthopedic clinics
• Ambulatory surgical centers (ASCs)
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE